3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Advanced Solid Tumor
12
Solid Tumor
6
Advanced Solid Tumors
5
Sarcoma
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Small Cell Lung Carcinoma
2
Mesothelioma
2
Melanoma
2
Carcinoma, Renal Cell
2
Anus Neoplasms
2
Advanced Solid Tumour
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Germ Cell Tumor
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Neoplasms, Unknown Primary
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Malignant Solid Tumors
1
MSI-H/dMMR Solid Tumors
1
MSI-H Colorectal Cancer
1
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
1
Locally Advanced or Metastatic Solid Tumors
1
Locally Advanced and Metastatic Solid Tumors
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
tislelizumab
×
Other solid neoplasm
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn